m 6 A‐Modified SNRPA Controls Alternative Splicing of ERCC1 Exon 8 to Induce Cisplatin Resistance in Lung Adenocarcinoma
Advanced Science · 2024
DOI: 10.1002/advs.202404609 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Weina Fan und 10 weiteren Autor:innen. Beteiligte Einrichtung: The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin, 150081, China. Hauptthemen laut MEDLINE: Cisplatin, Endonucleases, Adenocarcinoma of Lung, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation, Heilongjiang Provincial Postdoctoral Science Foundation.
Abstract (Originalsprache)
Alternative splicing (AS) generates protein diversity and is exploited by cancer cells to drive tumor progression and resistance to many cancer therapies, including chemotherapy. SNRPA is first identified as a spliceosome‐related gene that potentially modulates resistance to platinum chemotherapy. Both the knockout or the knockdown of SNRPA via CRISPR/Cas9 and shRNA techniques can reverse the resistance of cisplatin‐resistant lung adenocarcinoma (LUAD) cells to cisplatin. SNRPA overexpression enhanced the resistance of cisplatin‐sensitive LUAD cells. Gene Ontology (GO) analysis reveals that SNRPA is associated with DNA damage repair. Depletion of SNRPA induced ERCC1 exon 8 skipping and reduced ERCC1–XPF complex formation, whereas SNRPA overexpression exerted the opposite effect. siRNAs targeting isoforms containing ERCC1 exon 8 [ERCC1‐E8 (+)] reversed SNRPA‐enhanced cisplatin resistance and DNA damage repair. Furthermore, the IGF2BP protein, an m 6 A reader, and the ELAVL1 protein, an RNA stabilizer recruited by IGF2BP1, are found to bind to the SNRPA mRNA. ELAVL1 promoted cisplatin resistance, DNA repair and ERCC1‐E8 (+) expression in an SNRPA‐dependent manner. In a mouse xenograft model, SNRPA‐ KO CRISPR enhanced the sensitivity of LUAD cells to cisplatin. Overall, this study illuminates the role of SNRPA in platinum‐based drug resistance, thereby providing a novel avenue to potentially enhance chemosensitivity and improve the prognosis of patients with LUAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin, 150081, China.
- NHC and CAMS Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University, Harbin, 150001, China.
ORCID-Profile: Li Cai
Förderung
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Heilongjiang Provincial Postdoctoral Science Foundation
- Haiyan Foundation of Harbin Medical University Cancer Hospital
- Harbin Medical University Cancer Hospital
- Climing program of Harbin Medical University Cancer Hospital
- Outstanding Youth Fund Project of Harbin Medical University Cancer Hospital
Zitieren
APA
Fan, W., Huang, J., Tian, F., Hong, X., Zhu, K., Zhan, Y., Li, X., Wang, X., Wang, X., Cai, L., & Xing, Y. (2024). m 6 A‐Modified SNRPA Controls Alternative Splicing of ERCC1 Exon 8 to Induce Cisplatin Resistance in Lung Adenocarcinoma. Advanced Science. https://doi.org/10.1002/advs.202404609
Vancouver
Fan W, Huang J, Tian F, Hong X, Zhu K, Zhan Y, et al. m 6 A‐Modified SNRPA Controls Alternative Splicing of ERCC1 Exon 8 to Induce Cisplatin Resistance in Lung Adenocarcinoma. Advanced Science. 2024. doi:10.1002/advs.202404609
BibTeX
@article{Fan2024,
author = {Fan, Weina and Huang, Jian and Tian, Fanglin and Hong, Xin and Zhu, Kexin and Zhan, Yuning and Li, Xin and Wang, Xiangyu and Wang, Xin and Cai, Li and Xing, Ying},
title = {m 6 A‐Modified SNRPA Controls Alternative Splicing of ERCC1 Exon 8 to Induce Cisplatin Resistance in Lung Adenocarcinoma},
journal = {Advanced Science},
year = {2024},
doi = {10.1002/advs.202404609}
}
EUVIMED